Sanofi Reportedly Considers Acquisitions Of U.S. Biotechnology Companies

(RTTNews) - Sanofi (SNYNF, SNY) is considering potential acquisitions of U.S. biotechnology companies including Principia Biopharma as it seeks treatments for clinical areas including multiple sclerosis and immune disorders, Bloomberg reported citing people familiar with the matter.

Sanofi is working with advisers to study potential deals, the report said.

Sanofi could spend as much as $50 billion on acquisitions after announcing the disposal of its stake in Regeneron Pharmaceuticals Inc., Bloomberg reported in May.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More